http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2305238-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b1576ea6fb72be8646fe9cc84aaaa28
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
filingDate 2009-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0256b14823b15a9fb1ac309ba52a044f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0504e774a24909d4c86496bc4c6c430d
publicationDate 2011-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2305238-A1
titleOfInvention N-acetyl-L-cysteine for the treatment of endometriosis
abstract The invention relates to a new prescription of NAC in the treatment of endometriosis and of indications associated with endometriosis, in a human or mammalian animal patient. In addition an effective dose range of NAC in the treatment of endometriosis is proposed. In one embodiment of the present invention the prescribed treatment regimen may be used e.g. in order to control the frequency and the intensity of pain symptoms (dysmenorrhea, dyspareunia and acyckic chronic pelvic pain), to reduce the size of endometriotic lesions eventually up to their disappearance, to reduce recurrences after surgery and/or to improve fertility. Side effects of this treatment are virtually absent and, in particular, this treatment does not hinder pregnancy.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014166947-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014072350-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2789345-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9585854-B2
priorityDate 2009-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004014672-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004096206-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005048822-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003190381-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6239137-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007287676-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003119875-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128977994
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123959669
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6400
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226410671
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226521892
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226410670
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129787093
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21226166
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127986152
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16180
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID442514
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID316250
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1983
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396580
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409349
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395645
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14710
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12035
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23667301
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID327561614
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409987
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135985134

Total number of triples: 50.